Here are the 424B prospectus supplements from Neurogene, Inc. (NGNE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NGNE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NGNE filings page.
Neurogene Inc. is offering 3,500,000 shares of common stock and, in lieu of shares to certain investors, pre-funded warrants to purchase 666,666 shares. The public offering price is $30.00 per share. Net proceeds are expected to be approximately $117.2 million (or $134.8 million if the underwriters’ option is exercised in full). Delivery is expected on or about July 2, 2026. The prospectus supplement states the company intends to use proceeds to fund clinical development and pre-commercial activities for NGN-401, for working capital and general corporate purposes. Total common shares outstanding immediately after the offering are projected to be 19,115,786 (or 19,740,785 if the option is exercised in full), based on March 31, 2026 outstanding figures.
Neurogene Inc. proposes an offering of shares of common stock and pre-funded warrants to purchase common stock, together with shares issuable upon exercise of those warrants, via a preliminary prospectus supplement dated (subject to completion). The offering will fund continued development and pre-commercial activities for NGN-401 and for working capital.
The prospectus discloses 15,615,786 shares outstanding as of March 31, 2026, historical net tangible book value of $237.8 million ($15.23 per share) and recent Nasdaq closing price of $32.28 on June 29, 2026. Key terms include tradable common stock and non-listed pre-funded warrants exercisable at $0.000001 per share with ownership limitations.